Antony C.
- Country
- France
- Department
- Institut d’hématologie et d’oncologie pédiatrique (IHOP)
Research Overview
- Phase 1/2 Evaluation of Cobolimab and Dostarlimab in Pediatric and Young Adult Patients with Newly Diagnosed and Relapsed/Refractory Solid Tumors
- Evaluation of Palbociclib with Irinotecan and Temozolomide or Topotecan and Cyclophosphamide in Pediatric Recurrent/Refractory Solid Tumors
- Phase 1/2 Evaluation of Relatlimab and Nivolumab in Pediatric and Young Adult Patients with Recurrent or Refractory Classical Hodgkin and Non-Hodgkin Lymphoma
Data & Insights
Has run more than one trial at 19 of 59 partner sites.
Specializations
Pediatric Oncology
The investigator specializes in treating hematologic malignancies and solid tumors in pediatric and young adult patients, with particular emphasis on developing innovative therapeutic approaches.
- Classical Hodgkin Lymphoma
- Non-Hodgkin Lymphoma
- B-cell Acute Lymphoblastic Leukemia
Their work extends to evaluating novel treatment combinations for young patients with refractory conditions.
Solid Tumor Research
The investigator focuses on treating advanced and metastatic solid tumors, with specialized attention to rare pediatric cancers.
- Ewing Sarcoma
- Neuroblastoma
- Advanced Melanoma
Their research includes evaluating targeted therapies and immunotherapy approaches for resistant solid tumors.
Immunotherapy Applications
The investigator develops precision immuno-oncology treatments for various cancer types, focusing on novel therapeutic combinations.
- Antibody-Drug Conjugates
- Checkpoint Inhibitor Therapy
- Combination Immunotherapy
Their work encompasses biomarker-driven treatment approaches for optimal patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.